Similar articles

• The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.

  Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM. Lawrence B, et al. Endocrinol Metab Clin North Am. 2011 Mar;40(1):111-34, viii. doi: 10.1016/j.ecl.2010.12.001. Endocrinol Metab Clin North Am. 2011. PMID: 21349414 Review.
• Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors.

  Massironi S, Conte D, Sciola V, Spampatti MP, Ciafardini C, Valenti L, Rossi RE, Peracchi M. Massironi S, et al. Am J Gastroenterol. 2010 Sep;105(9):2072-8. doi: 10.1038/ajg.2010.154. Epub 2010 Apr 6. Am J Gastroenterol. 2010. PMID: 20372113
• Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.

  Singh S, Law C. Singh S, et al. Expert Rev Gastroenterol Hepatol. 2012 Jun;6(3):313-34. doi: 10.1586/egh.12.15. Expert Rev Gastroenterol Hepatol. 2012. PMID: 22646254 Review.
• Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.

  Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, Scherag A, Hahmann M, Müller HH, Barth P. Arnold R, et al. Clin Gastroenterol Hepatol. 2008 Jul;6(7):820-7. doi: 10.1016/j.cgh.2008.02.052. Epub 2008 Jun 10. Clin Gastroenterol Hepatol. 2008. PMID: 18547872
• Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.

  Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Modlin IM, et al. Ann Surg Oncol. 2010 Sep;17(9):2427-43. doi: 10.1245/s10434-010-1006-3. Epub 2010 Mar 9. Ann Surg Oncol. 2010. PMID: 20217257 Review.